PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION CONCERNING
TRANSMITTAL OF COPY OF INTERNATIONAL
PRELIMINARY REPORT ON PATENTABILITY
(CHAPTER I OF THE PATENT COOPERATION
TREATY)

(PCT Rule 44bis.1(c))

SUTCLIFFIE, Nichoja NOV 2005

Mewburn Ellis LLP NOV 2005

York House
23 Kingsvie MEWOUN ELLIS LLP

London

Greater London WC2B 6HP

ROYAUME-UNI

Date of mailing (day/month/year) 27 October 2005 (27.10.2005)

Applicant's or agent's file reference NRSLP6215388

IMPORTANT NOTICE

International application No. PCT/GB2004/001455

International filing date (day/month/year) 02 April 2004 (02.04.2004)

Priority date (day/month/year) 03 April 2003 (03.04.2003)

Applicant

UCL BIOMEDICA PLC et al

The International Bureau transmits herewith a copy of the international preliminary report on patentability (Chapter I of the Patent Cooperation Treaty)

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

Nora Lindner

Facsimile No.+41 22 740 14 35

Facsimile No.+41 22 338 89 65

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference NRSLP6215388	FOR FURTHER ACTION	See item 4 below	
International application No. PCT/GB2004/001455	International filing date (day/month/year) 02 April 2004 (02.04.2004)	Priority date (day/month/year) 03 April 2003 (03.04.2003)]	
International Patent Classification (IPC) or national classification and IPC 7 A61L 27/38, 27/40			
Applicant UCL BIOMEDICA PLC			

1.	This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 bis.1(a).		
2.	This REPORT consists of a total of 9 sheets, including this cover sheet.		
	In the attached sheets, any reference to the written opinion of the International Searching Authority should be read as a reference to the international preliminary report on patentability (Chapter I) instead.		
3.	This report contains indications relating to the following items:		
	Box No. I	Basis of the report	
	Box No. II	Priority	
	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability	
	Box No. IV	Lack of unity of invention	
	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement	
	Box No. VI	Certain documents cited	
	Box No. VII	Certain defects in the international application	
	Box No. VIII	Certain observations on the international application	
4.	1. The International Bureau will communicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but not, except where the applicant makes an express request under Article 23(2), before the expiration of 30 months from the priority date (Rule 44bis.2).		
		Date of issuance of this report	

	Date of issuance of this report 14 October 2005 (14.10.2005)
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Nora Lindner
Facsimile No. +41 22 740 14 35	Telephone No. +41 22 338 89 65

Form PCT/IB/373 (January 2004)

PATENT COOPERATION TREATY

	From the					
	INTERNATIONAL SEARCHING AUTHORITY				REC'D 20	JUL 2004
То	:				P()1	568 500 [
					WIPO	PCT
see form PCT/ISA/220			WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43 <i>bis</i> .1)			
				Date of mailing (day/month/year) see form PCT/ISA/210 (second sheet)		eet)
App	licant's or agent's file	e reference				
	form PCT/ISA/2			FOR FURTHER ACTION See paragraph 2 below		
	rnational application		International filing date (dav/month/vear)	Priority date (day/month/year)
PC	T/GB2004/00145	55	02.04.2004	, ,	03.04.2003	,
Inte	national Patent Clas	sification (IPC) or I	both national classification	and IPC		
	IL27/38, A61L27	/40			•	
1	licant L BIOMEDICA P					
	L BIOWEDICA P	~LC				
1.	This opinion co	ontains indicatio	ons relating to the follo	owing items:		
	☑ Box No. I	Basis of the op	inion			,
	☑ Box No. II	Priority				
	☑ Box No. III	Non-establishm	nent of opinion with rega	gard to novelty, inventive step and industrial applicability		
	Box No. IV	Lack of unity of	invention		терриос	.G,iicy
	Box No. V Reasoned statement under Rule 43bis applicability; citations and explanations			.1(a)(i) with regard to r	novelty, inventive step or inc	dustrial
	Box No. VI Certain documents cited			· capporting such state	anont	
	☐ Box No. VII Certain defects in the international app		in the international app	lication		
	☐ Box No. VIII		ations on the internation			
2.	FURTHER ACTI			,,		
If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notifed the International Bureau under Rule 66.1 bis(b) that written opinions of this International Searching Authority will not be so considered.			. 1			
	adduling to the H	date of mailing o	TOOLEHNER WHERE APPROX	Mata with amondmon	PEA, the applicant is invited ts, before the expiration of the factorial fac	i t
	For further options, see Form PCT/ISA/220.					
3.	,					
Name	and mailing address	s of the ISA:		Authorized Officer		
						has Velenia



European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465

Bochelen, D

Telephone No. +49 89 2399-8150



International application No. PCT/GB2004/001455

Box No. I Basis of the opinion			
1. With regard to the language, this opinion has been established on the basis of the international application in the language in which it was field, unless otherwise indicated under this item.			
This opinion has been established on the basis of a translation from the original language into the following language , which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).			
With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:			
a. type of material:			
a sequence listing			
☐ table(s) related to the sequence listing			
b. format of material:			
☐ in written format			
☐ in computer readable form			
c. time of filing/furnishing:			
contained in the international application as filed.			
filed together with the international application in computer readable form.			
furnished subsequently to this Authority for the purposes of search.			
In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.			
Additional comments:			

International application No. PCT/GB2004/001455

_	Box No. II Priority				
_					
1.	\boxtimes	The fo	llowing document has not been furnished:		
		X	CODY of the earlier application where the same state of the same s		
			copy of the earlier application whose priority has been claimed (Rule 43bis.1 and 66.7(a)).		
			translation of the earlier application whose priority has been claimed (Rule 43bis.1 and 66.7(b)).		
		^	(Rule 43 <i>bis.</i> 1 and 66.7(b)).		
		neverth	quently it has not been possible to consider the validity of the priority claim. This opinion has neless been established on the assumption that the relevant date is the claimed priority date.		
2.		This op	onion has been established as if no priority had been claimed due to the fact that the priority claim en found invalid (Rules 43 <i>bis</i> .1 and 64.1). Thus for the purposes of this opinion, the international ate indicated above is considered to be the relevant date.		
3.	Add		bservations, if necessary:		

International application No. PCT/GB2004/001455

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability					
Th ob	The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:				
\boxtimes	claims Nos. 26 -30				
be	because:				
Ø	the said international application, or the said claims Nos. 26-30 relate to the following subject matter which does not require an international preliminary examination (specify):				
	see separate sheet				
	the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):				
	the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.				
\boxtimes	no international search report has been established for the whole application or for said claims Nos				
	the written form		has not been furnished		
			does not comply with the standard		
	the computer readable form		has not been furnished		
			does not comply with the standard		
	the tables related to the nucleo not comply with the technical re	e tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do t comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.			
	See separate sheet for further of	detail	s		

International application No. PCT/GB2004/001455

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-30

No: Claims

Inventive step (IS)

Yes: Claims

No: Claims

Industrial applicability (IA)

Yes: Claims

1-25

1-30

No: Claims

2. Citations and explanations

see separate sheet

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. Claims 26-30 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

- 2. Reference is made to the following documents:
 - D1: US-A-5 756 350 (HUANG DAVID ET AL) 26 May 1998 (1998-05-26)
 - D2: US-B-6 174 3331 (KADIYALA SUDHAKAR ET AL) 16 January 2001 (2001-01-16)
 - D3: WO 02/47557 A (PEARSON RICHARD; UNIV NOTTINGHAM (GB); SHAKESHEFF KEVIN (GB)) 20 June 2002 (2002-06-20)
 - D4: CHEN Y-S ET AL: "Peripheral nerve regeneration using silicone rubber chambers filled with collagen, laminin and fibronectin" BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 21, no. 15, August 2000 (2000-08), pages 1541-1547, XP004204628 ISSN: 0142-9612
 - D5: US-B-6 171 6101 (VACANTI CHARLES A ET AL) 9 January 2001 (2001-01-09)
 - D6: HENTZ V R ET AL: "The nerve gap dilemma: a comparison of nerves repaired end to end under tension with nerve grafts in a primate model." THE JOURNAL OF HAND SURGERY. MAY 1993, vol. 18, no. 3, May 1993 (1993-05), pages 417-425, XP009033626 ISSN: 0363-5023

If not indicated otherwise the relevant passages are those mentioned in the search report.

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (SEPARATE SHEET)

International application No.

PCT/GB2004/001455

Document D1 discloses an oriented tissue equivalent obtained by growing cells in a collagen gel. The axis of contraction of the cells is defined by two spaced structures.

Document D2 discloses an implant for repairing a tissue comprising load bearing structures and a gel matrix, e.g. collagen, with cells seeded therein, the cells having contracted the gel in a given direction.

Document D3 discloses a guide for nerve regeneration comprising a tubular conduit filled with a hydrogel like collagen, fibrin or agarose.

Document D4 discloses a guide for nerve regeneration comprising a silicone tube filled with collagen, laminin and fibronectin.

Document D5 discloses a tissue regeneration device, e.g. for spinal cord, comprising a permeable support structure, e.g. a cylinder, filled with hydrogel and tissue precursor cells, e.g. fibroblasts.

Document D6 is a study comparing the nerve regeneration under tension with nerve grafts.

- 3. Novelty (Art. 33(1)(2) PCT):
- 3.1 None of the documents of the prior art discloses a tissue growth guide as claimed in claim 1. The subject-matter of claim 1 is thus new.
- 3.2 None of the documents of the prior art discloses a method for making tissue growth guide as claimed in claim 23. Claim 23 is thus new.
- 3.3 None of the documents of the prior art discloses a the use of a tissue growth guide according to claim 1 for repairing tissue. Claim 29 is thus new.
- 4. Inventive step (Art. 33(1)(3) PCT):
- 4.1 Document D1 (alternatively D2) is the closest prior art and discloses an oriented tissue equivalent obtained by growing cells in a collagen gel wherein the gel is contracted by the cells along an axis defined by two spaced structures. The subject-matter of claim 1 differs in that the guide comprises an outer sheath. The

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (SEPARATE SHEET)

International application No.

PCT/GB2004/001455

problem to be solved can thus be regarded as to provide an alternative tissue growth guide. Documents D3 and D4 disclose a nerve regeneration device comprising a tubular component filled with hydrogel and biopolymers. It would be obvious to combine the teaching of D1 with D3 and D4 in order to solve the problem. Consequently, an inventive step is not acknowledged for claim 1.

- 4.2 Document D1 discloses that the cells align along a defined axis defined by two fixed posts (see D1 col6 l29-44). A skilled man would thus consider to fix the cell-containing hydrogel in order to induce the alignment of the cells and the tension. Claim 23 does thus not involve an inventive step.
- 4.3 It would be obvious in view of D1 combined with D3-D4 to use the guide as claimed in claim 29. Said claim is thus not inventive.
- 4.4 Dependent claims 2-22, 24-28 and 30 do not contain any features which, in combination with the features of any claim to which they refer, meet the requirements of the PCT in respect of inventive step.
- 5. Industrial applicability (Art. 33(1)(4) PCT):

For the assessment of the present claims 26-30 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.